Finerenone for Chronic Kidney Disease
(FIND-CKD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing finerenone, a daily pill, to help people with non-diabetic chronic kidney disease. Finerenone works by blocking a hormone called aldosterone that can cause damage and swelling in the heart and kidneys. The goal is to see if finerenone can slow down the worsening of kidney disease. Finerenone has shown promise in reducing kidney disease progression in patients with chronic kidney disease and type 2 diabetes.
Will I have to stop taking my current medications?
No, you will not have to stop taking your current medications for chronic kidney disease. Participants will continue their existing CKD medications while taking the trial treatment.
Is Finerenone safe for humans?
What makes the drug Finerenone unique for treating chronic kidney disease?
Finerenone is unique because it is a first-in-class, third-generation, nonsteroidal mineralocorticoid receptor antagonist (MRA) that specifically targets kidney and heart complications in patients with chronic kidney disease and type 2 diabetes. Unlike older MRAs, it has a lower risk of causing hyperkalemia (high potassium levels), making it a safer option for long-term use.678910
What data supports the effectiveness of the drug Finerenone for chronic kidney disease?
Are You a Good Fit for This Trial?
Adults with non-diabetic chronic kidney disease (CKD) can join this trial. They must have a certain level of protein in their urine and a specific range of kidney function. Participants should be on stable doses of ACE inhibitors or ARBs for at least 4 weeks before the trial starts, without severe heart failure or diabetes, and not require immunosuppressive therapy for other kidney diseases.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive finerenone or placebo once a day as tablets by mouth, in addition to their current CKD medication
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Finerenone
- Placebo
Finerenone is already approved in United States, European Union for the following indications:
- Chronic kidney disease associated with type 2 diabetes
- Chronic kidney disease associated with type 2 diabetes
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bayer
Lead Sponsor
Bill Anderson
Bayer
Chief Executive Officer since 2023
BSc in Chemical Engineering from the University of Texas, MSc in Chemical Engineering and Management from MIT
Michael Devoy
Bayer
Chief Medical Officer since 2014
MD, PhD